GlassScriptPhysician profile
Tara V Saco
NPI 1104245174
$45,933.19
in general payments reported to CMS, 2019-2025
24 companies · $20K in 2025
The $20K reported for 2025 was more than what 92% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $818 · 2021: $985 · 2022: $1,042 · 2023: $15.75 · 2024: $22K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $35K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,655 · Travel and Lodging: $2,370 · Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $34,836.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,655.00 |
| Travel and Lodging | $2,370.13 |
| Food and Beverage | $623.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $38,886.45 | 2021-2025 | Ayvakit |
| Sanofi US Services INC. | $4,655.00 | 2025 | |
| Glaxosmithkline, LLC. | $452.66 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $263.16 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $198.70 | 2019-2021 | |
| Octapharma USA, INC. | $178.59 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $175.24 | 2019-2021 | |
| Genzyme Corporation | $171.20 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $144.88 | 2019-2020 | |
| Kaleo, INC. | $113.15 | 2019-2021 | |
| Pfizer INC. | $111.84 | 2019-2021 | |
| Optinose US, INC. | $96.65 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $94.63 | 2020-2021 | |
| Shire North American Group INC | $78.65 | 2019 | |
| Genentech USA, INC. | $75.48 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $50.06 | 2020-2021 | |
| Covis Pharma Gmbh | $43.36 | 2021 | |
| Grifols USA, LLC | $30.66 | 2021 | |
| Horizon Therapeutics Plc | $28.45 | 2020 | |
| Mylan Specialty L.P. | $23.26 | 2020 | |
| Phadia US INC. | $18.85 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.57 | 2021 | |
| Aimmune Therapeutics, INC. | $12.56 | 2020 | |
| Alk-Abello, INC | $12.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Saco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.